BridgeBio Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by BridgeBio Pharma, Inc. (the "Company") on November 19, 2019, covering events occurring on November 13, 2019, and November 16, 2019. The Company is an emerging growth company incorporated in Delaware. The filing primarily addresses a material definitive agreement entered into by Eidos Therapeutics, Inc. ("Eidos"), a partially-owned subsidiary in which the Company held a 66.3% interest as of September 30, 2019.
Key Financial Metrics and Debt
The filing details a new debt facility rather than reporting standard operating financial metrics such as revenue or net income for a specific period.
- Term Loan Amount: Up to $55,000,000.
- Lenders: Silicon Valley Bank and Hercules Capital, Inc.
- Interest Rate: Floating rate equal to the greater of 8.5% or 3.25% above the Wall Street Journal Prime Rate.
- Maturity Date: October 2, 2023.
- Repayment Structure: Monthly interest-only payments until November 1, 2021 (extendable to May 2, 2022 upon meeting a clinical milestone). A final payment on the Maturity Date includes all outstanding principal, accrued interest, and a "Final Payment" equal to 5.95% of the original aggregate principal amount.
- Upfront Costs: Non-refundable commitment fee of $275,000 plus reimbursement of certain lender expenses.
- Collateral: Substantially all of Eidos's assets, excluding intellectual property.
- Use of Proceeds: General corporate purposes.
The filing text does not provide clear values for the Company's total revenue, profit, cash flow, or overall liquidity position as of the filing date.
Material Changes and Other Events
There are no comparative financial changes reported in this filing as it is a current report regarding specific events. The material changes include:
- Debt Incurrence: Eidos entered into a Loan and Security Agreement, creating a new liability of up to $55 million.
- Clinical Data Update: On November 16, 2019, the Company issued a press release regarding Phase 2 Open Label Extension data for AG10, suggesting long-term tolerability and stabilization of disease measures in Transthyretin Amyloid Cardiomyopathy.
Guidance, Risks, and Contingencies
The filing does not contain updated financial guidance or management commentary on future earnings. However, it outlines specific risks and contingencies associated with the new loan:
- Covenants: Eidos must maintain customary financial covenants, representations, and warranties.
- Events of Default: Include non-payment, covenant violations, bankruptcy, and material judgments.
- Prepayment: Eidos may prepay the loan subject to a prepayment fee and the Final Payment obligation.
- Reborrowing: Once repaid, amounts borrowed under the Term Loan may not be reborrowed.
Key Facts for Investor Verification
- Verify the exact drawdown amount of the $55 million Term Loan, as the agreement allows for loans "up to" this amount.
- Confirm the current status of the clinical data milestone required to extend the interest-only period to May 2022.
- Review the full Loan and Security Agreement (Exhibit 10.1) for specific financial covenants that could trigger a default.
- Assess the impact of the 5.95% Final Payment on the total cost of capital for the subsidiary.
- Monitor the Phase 2 data for AG10 as referenced in the November 16 press release for potential impacts on future valuation or partnership opportunities.